<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical use of monoclonal antibody disease-modifying therapies for multiple sclerosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical use of monoclonal antibody disease-modifying therapies for multiple sclerosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical use of monoclonal antibody disease-modifying therapies for multiple sclerosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Olek, DO</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ellen Mowry, MD, MCR</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francisco González-Scarano, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1808434303"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Multiple sclerosis (MS) is an immune-mediated inflammatory demyelinating disease of the central nervous system that is a leading cause of disability in young adults. Disease-modifying therapies (DMTs) for MS are drugs that effectively reduce the relapse rate and the development of new lesions for patients with MS.</p><p>The indications, efficacy, dose, administration, monitoring, and adverse effects of the monoclonal antibody DMTs for MS are discussed in this topic review. Other DMTs for MS are reviewed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>Oral DMTs (see  <a class="medical medical_review" href="/d/html/143125.html" rel="external">"Clinical use of oral disease-modifying therapies for multiple sclerosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Platform injection therapies (see  <a class="medical medical_review" href="/d/html/129091.html" rel="external">"Overview of disease-modifying therapies for multiple sclerosis", section on 'Platform therapies'</a>)</p><p></p><p class="headingAnchor" id="H4001130462"><span class="h1">CHOOSING THERAPY</span><span class="headingEndMark"> — </span>There are multiple disease-modifying therapies (DMTs) for MS, including older platform injection therapies, monoclonal antibodies, and oral agents.</p><p>Monoclonal antibodies for MS include <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a>, <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">ocrelizumab</a>, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9523" href="/d/drug information/9523.html" rel="external">ofatumumab</a>, <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a>, and <a class="drug drug_general" data-topicid="140396" href="/d/drug information/140396.html" rel="external">ublituximab</a>. These DMTs are highly efficacious for reducing the relapse rate in patients with MS, but serious safety issues, including infections, are possible adverse effects of several of these medications. Thus, monoclonal antibody DMTs may be preferred for patients with more active disease and for those who place a high value on efficacy and are risk-tolerant.</p><p>However, there is no uniform method for choosing the best DMT for an individual patient. The choice of a specific agent for patients with MS should be individualized according to disease activity, comorbid conditions, and patient values and preferences  (<a class="graphic graphic_algorithm graphicRef102519" href="/d/graphic/102519.html" rel="external">algorithm 1</a>).</p><p>The use of DMT for specific clinical situations is discussed in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1691.html" rel="external">"Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1687.html" rel="external">"Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/129095.html" rel="external">"Indications for switching or stopping disease-modifying therapy for multiple sclerosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1686.html" rel="external">"Treatment of secondary progressive multiple sclerosis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/128298.html" rel="external">"Treatment of primary progressive multiple sclerosis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/135221.html" rel="external">"Multiple sclerosis: Pregnancy planning"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/138599.html" rel="external">"Multiple sclerosis: Pregnancy and postpartum care"</a>.)</p><p></p><p>The treatment of acute MS exacerbations is also reviewed separately. (See  <a class="medical medical_review" href="/d/html/1698.html" rel="external">"Treatment of acute exacerbations of multiple sclerosis in adults"</a>.)</p><p class="headingAnchor" id="H2713145496"><span class="h1">INTEGRIN ANTAGONIST THERAPY</span></p><p class="headingAnchor" id="H576330025"><span class="h2">Natalizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">Natalizumab</a> is a recombinant monoclonal antibody directed against the alpha-4 subunit of integrin molecules, thereby blocking integrin association with vascular receptors and limiting adhesion and transmigration of leukocytes. In patients with MS, natalizumab treatment is associated with a diminished migratory capacity of immune cells and a prolonged decrease in lymphocyte counts in the cerebrospinal fluid (CSF) [<a href="#rid1">1,2</a>].</p><p>Natalizumab-sztn is a biosimilar product that has no clinically meaningful differences from <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H2251532619"><span class="h3">Indications</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">Natalizumab</a> is indicated as monotherapy for the treatment of relapsing forms of MS, including clinically isolated syndromes (CIS), relapsing-remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis (SPMS).</p><p><a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">Natalizumab</a> is <strong>contraindicated</strong> in patients who have or have had progressive multifocal leukoencephalopathy (PML) and in patients with a previous hypersensitivity reaction to natalizumab. Because of the risk of PML, natalizumab should not be used for patients who may have impaired immunity, such as hematologic or rheumatologic conditions associated with compromised cell-mediated immunity [<a href="#rid4">4,5</a>].</p><p class="headingAnchor" id="H977735081"><span class="h3">Dose and administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">Natalizumab</a> is given as a 300 mg intravenous (IV) infusion over one hour, every four weeks. In the United States, infusions are given in centers registered under the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F74177%2Fdownload&amp;token=8RYIFfyLhIBYEqeX7m6uPATsE%2BQtH2WXOvtlcnSWVzOsxbPCo10P1mU2zrc5jaPCrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=143122" target="_blank">TOUCH</a> program. Patients should be observed for any signs or symptoms consistent with hypersensitivity reaction during the infusion and for one hour after the infusion is complete. Natalizumab should be discontinued in patients who develop hypersensitivity reactions.</p><p class="headingAnchor" id="H2576383633"><span class="h3">Extended interval dosing</span><span class="headingEndMark"> — </span>Among patients treated with <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> who are seropositive for JC polyomavirus (JCV) antibody, observational data suggest that dosing natalizumab every five to eight weeks rather than every four weeks may reduce the risk of PML without reducing efficacy [<a href="#rid6">6-12</a>], but this approach is not yet optimized.</p><p>In a retrospective cohort study that analyzed over 35,000 patients from the TOUCH database who were seropositive for the anti-JCV antibody, <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> extended interval dosing was associated with a lower risk of PML than standard interval dosing [<a href="#rid10">10</a>]. A later study from the same investigators, published in abstract form, updated data from the TOUCH program and also found that extended interval dosing was associated with a lower risk of PML [<a href="#rid8">8</a>]. In the open-label, randomized NOVA trial, which enrolled 499 patients, extended interval dosing compared with standard interval dosing of natalizumab was associated with a higher estimated number of new or enlarging T2 hyperintense lesions at week 72; the difference reached statistical significance in one of the two prespecified analysis methods, and, notably, most of the new magnetic resonance imaging (MRI) activity was driven by two outliers in the extended interval dosing group [<a href="#rid13">13</a>]. The safety profiles of the two dosing groups were similar. Several small studies found that extended interval dosing was not associated with an increase in neurofilament light serum levels, a proposed biomarker of MS disease activity [<a href="#rid9">9,14</a>].</p><p>In a subsequent prospective study of 61 patients with RRMS who were free of disease activity on <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> for at least one year, natalizumab treatment intervals were personalized according to natalizumab trough levels [<a href="#rid7">7</a>]. The dosing interval was increased by one week if the natalizumab trough level was ≥15 mcg/mL, targeting a natalizumab trough level of 10 mcg/mL. This method extended the dosing interval to five to seven weeks for 51 patients and retained the standard four-week dosing interval for 10 patients. For patients on extended interval dosing who completed one year of follow-up (n = 48) and a one-year extension phase (n = 24), none developed relapses or new or enlarging MRI lesions.</p><p>The utility of extended interval dosing needs confirmation, ideally in a larger clinical trial, but such extended interval dosing is a potential option when <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> is continued despite conversion to seropositivity for the JCV.</p><p class="headingAnchor" id="H3042539057"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">Natalizumab</a> treatment is associated with a risk of developing PML, a rare, potentially fatal neurologic disease caused by reactivation of JCV infection. (See <a class="local">'Surveillance for PML'</a> below and  <a class="medical medical_review" href="/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis", section on 'Epidemiology'</a>.)</p><p>The most frequent adverse events associated with <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> treatment include infusion-related symptoms (headache, flushing, erythema, nausea, and dizziness), fatigue, infections (mainly urinary tract and lower respiratory tract infections), arthralgia, gastroenteritis, vaginitis, extremity pain, depression, and rash [<a href="#rid15">15,16</a>]. Other than PML, opportunistic infections are rarely associated with natalizumab therapy; they have included cases of herpes zoster, herpes meningitis, herpes simplex virus encephalitis, and tuberculosis [<a href="#rid15">15,17,18</a>]. Hepatoxicity, including clinically significant liver injury, and thrombocytopenia have been reported in postmarketing data [<a href="#rid19">19,20</a>]. Neonatal thrombocytopenia has been reported in newborns exposed to natalizumab in utero [<a href="#rid16">16</a>].</p><p>As of July 2022, there were 892 cases of natalizumab-associated PML reported worldwide [<a href="#rid21">21</a>]. The risk of natalizumab-associated PML for an individual patient varies according to the following factors  (<a class="graphic graphic_table graphicRef55637" href="/d/graphic/55637.html" rel="external">table 1</a>) [<a href="#rid22">22-26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-JCV antibody status</p><p class="bulletIndent1"><span class="glyph">●</span>Prior immunosuppressant treatment</p><p class="bulletIndent1"><span class="glyph">●</span>Duration of <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> exposure</p><p></p><p>Detailed PML risks are provided in the figure  (<a class="graphic graphic_figure graphicRef114063" href="/d/graphic/114063.html" rel="external">figure 1</a>) [<a href="#rid27">27</a>]. The estimated risk of PML is low (&lt;1:10,000) for patients who are seronegative for anti-JCV antibodies but increases with seroconversion, the strength of the seropositive response, and the duration of <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> exposure for seropositive patients. (See <a class="local">'Surveillance for PML'</a> below.)</p><p>In postmarketing data as of June 2017, the number of <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> doses received before the diagnosis of PML ranged from 8 to 136 (mean approximately 49) [<a href="#rid28">28</a>]. In the United States, the number of prior natalizumab infusions for an individual patient can be determined by contacting the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F74177%2Fdownload&amp;token=8RYIFfyLhIBYEqeX7m6uPATsE%2BQtH2WXOvtlcnSWVzOsxbPCo10P1mU2zrc5jaPCrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=143122" target="_blank">TOUCH</a> program.</p><p class="headingAnchor" id="H2839957998"><span class="h3">Screening and monitoring</span><span class="headingEndMark"> — </span>When there is suspicion for PML, <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> should be discontinued [<a href="#rid22">22</a>]. Thus, surveillance for PML is a critical aspect of natalizumab treatment. (See <a class="local">'Surveillance for PML'</a> below.)</p><p>The management of natalizumab-related PML is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1697.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Treatment and prognosis", section on 'Natalizumab-associated PML'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Before starting</strong> – Whenever possible, leukocyte and neutrophil counts should be within or close to the normal range. We suggest stopping glucocorticoids and most other immunosuppressive medications, including <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> and monoclonal antibody disease-modifying therapies (DMTs), for at least one month prior to starting <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a>, but a prolonged washout may not be necessary for beta interferons, <a class="drug drug_general" data-topicid="8490" href="/d/drug information/8490.html" rel="external">glatiramer acetate</a>, or oral DMTs other than cladribine. <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">Cholestyramine</a> may be used to accelerate the removal of <a class="drug drug_general" data-topicid="86616" href="/d/drug information/86616.html" rel="external">teriflunomide</a>. A longer washout period (up to three months or more) is suggested for <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>, <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>, and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> [<a href="#rid4">4</a>]. A baseline brain MRI scan should be obtained prior to initiating therapy with natalizumab, since it is useful in comparison with later MRI scans for detecting changes suggestive of PML.</p><p></p><p class="bulletIndent1">However, this goal may not be feasible for people switching from a sphingosine 1-phosphate receptor (S1PR) modulator, where waiting for normalization of lymphocyte count is associated with increased risk of rebound disease; similarly, people switching from a fumarate may need to be individually counseled about the pros and cons of waiting for normalization of lymphocytes prior to switching to <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> (or any other MS therapy). In most cases, active MS is the indication for switching (escalation) to a higher efficacy medication (natalizumab); waiting for normalization of lymphocytes increases the risk of further MS activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibodies to </strong><strong>natalizumab</strong> – Antibodies to <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> are not routinely obtained in clinical practice, but limited data suggest they may be useful in select patients with infusion reactions or poor response to natalizumab. However, it is more common in these scenarios to switch to a different DMT rather than obtain natalizumab antibody studies. Antibodies to natalizumab developed in approximately 9 percent of patients in the AFFIRM and SENTINEL trials and were persistently positive in approximately 6 percent [<a href="#rid29">29</a>]. When compared with antibody negativity, persistent anti-natalizumab antibody positivity was associated with reduced clinical effectiveness of natalizumab treatment and with an increased incidence of infusion reactions.</p><p></p><p class="headingAnchor" id="H3275503418"><span class="h3">Surveillance for PML</span><span class="headingEndMark"> — </span>PML is rare in the first year of <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> therapy even among those who are seropositive at baseline for anti-JCV antibodies. In patients with a negative or low JCV antibody level, most studies suggest that approximately 97 percent remain low over an 18-month period. However, the risk increases in patients who are seropositive for anti-JCV antibodies and with longer duration of natalizumab therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk management program</strong> – For patients treated with <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a>, rigorous clinical and neuroimaging follow-up is essential to detect the onset of symptoms and signs related to PML as opposed to those related to MS [<a href="#rid22">22</a>]. Natalizumab is available in the United States through a risk management program (the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F74177%2Fdownload&amp;token=8RYIFfyLhIBYEqeX7m6uPATsE%2BQtH2WXOvtlcnSWVzOsxbPCo10P1mU2zrc5jaPCrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=143122" target="_blank">TOUCH</a> risk minimization action plan) that requires enrollment by prescribers, specialty pharmacies, and infusion centers that dispense the drug [<a href="#rid30">30</a>]. Clinicians must evaluate patients at three and six months after natalizumab treatment is started, and at least every six months thereafter. Patients receiving natalizumab must enroll in a mandatory registry and complete a checklist that asks about medications and new symptoms suggestive of PML prior to monthly infusions. Monitoring programs and registries for natalizumab prescribing are in place in several other countries as well.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>JCV antibody testing</strong> – We strongly suggest testing for anti-JCV antibodies <strong>at baseline</strong> and <strong>every six months </strong>while on <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> therapy  (<a class="graphic graphic_table graphicRef106610" href="/d/graphic/106610.html" rel="external">table 2</a>). For patients who are seropositive and without prior immunosuppressive treatment, determination of anti-JCV antibody levels, as measured by the anti-JCV antibody index, may improve the accuracy of PML risk stratification [<a href="#rid25">25</a>]. The index allows quantification of anti-JCV antibody levels for individual patients and is calculated by normalizing the optical density of the anti-JCV antibody serum sample with a calibrator [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1">In contrast to testing for anti-JCV antibodies, testing for JCV deoxyribonucleic acid (DNA) in blood or urine appears to have no utility for determining the risk of PML. The authors have noted with some frequency that despite ordering JCV antibody testing, some commercial laboratories have erroneously run the JCV polymerase chain reaction (PCR) instead. Therefore, it is important to verify that the correct test (the anti-JCV antibody assay) was done when results come in.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>JCV antibody status</strong> – The JCV antibody status, JCV antibody index, history of prior immunosuppressant exposure, and duration of <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> exposure can be used to estimate the risk of PML and to guide decisions concerning natalizumab therapy  (<a class="graphic graphic_figure graphicRef114063" href="/d/graphic/114063.html" rel="external">figure 1</a>) [<a href="#rid25">25,31,32</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who <strong>remain seronegative</strong> for anti-JCV antibodies, the estimated risk of PML is &lt;1:10,000, suggesting relative safety of continuing <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> as indicated for MS. However, vigilance for PML is still required, as illustrated by a case report of a patient who had a negative anti-JCV antibody test two weeks prior to being diagnosed with PML [<a href="#rid27">27</a>]. Suggested monitoring involves repeating the anti-JCV antibody test every six months and a brain MRI every 12 months of natalizumab exposure. Although a negative JCV antibody test is often used to signify safety of therapy for indefinite periods of time, there is limited documented experience with long-term (more than six years) natalizumab therapy [<a href="#rid33">33-36</a>]. In one retrospective report of patients treated with natalizumab for more than six months, the median time from a negative JCV index value at baseline to JCV seroconversion based upon survival analysis was 103 months; the annualized seroconversion rate was 5.8 percent [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who are <strong>seropositive or seroconvert</strong> to positive anti-JCV status, and who have <strong>no</strong> prior use of immunosuppressant medications, the estimated risk of PML varies with the strength of the seropositive response or the antibody index; higher antibody levels are associated with a higher risk.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>With an anti-JCV antibody index &lt;0.9, the estimated risk of PML is &lt;1:10,000 for months 1 to 24 and 1:748 for &gt;24 months of <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> exposure  (<a class="graphic graphic_table graphicRef106610" href="/d/graphic/106610.html" rel="external">table 2</a>) [<a href="#rid25">25,31,32</a>]. Suggested monitoring involves repeating the anti-JCV antibody index every six months and a brain MRI every 12 months of natalizumab exposure. At a minimum, clinicians should counsel the patient about the risks of continuing natalizumab therapy beyond 24 months, although it should be cautioned that PML risk is cumulative rather than only beginning at the 24-month period.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>With an anti-JCV antibody index of ≥0.9, the estimated risk of PML is &lt;1:1062 for months 1 to 24 and 1:101 for &gt;24 months of <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> exposure  (<a class="graphic graphic_table graphicRef106610" href="/d/graphic/106610.html" rel="external">table 2</a>). Suggested monitoring involves repeating the MRI scan at 12 months and then every six months beginning at 18 months of natalizumab exposure. For patients with an index of ≥0.9, we suggest stopping natalizumab after 24 months of treatment and transitioning to another DMT because of the mounting risk of PML, or extending the dosing interval of natalizumab even before 24 months. (See <a class="local">'Extended interval dosing'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>With an anti-JCV antibody index of ≥1.5, a conservative approach is to avoid <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> and use an alternate DMT for initial or escalation therapy.</p><p></p><p class="bulletIndent2">Some experts, including one author of this topic (EM), do not routinely use <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> for patients who are anti-JCV antibody positive at baseline. They also favor switching from natalizumab to another DMT as soon as possible if patients seroconvert to positive anti-JCV antibody status during natalizumab treatment, particularly if they have a high titer, with appropriate counseling about the pros and cons of doing so.</p><p></p><p class="bulletIndent2">The rationale for switching to another DMT immediately upon seroconversion is that the risk of PML is cumulative with <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> treatment; continued natalizumab exposure drives up risk, which may theoretically be compounded by the potential for a short period of heightened PML risk when switching to the next DMT. However, reducing PML risk by simply stopping natalizumab for a washout period carries an unacceptable risk of MS rebound. It is reasonable to obtain a brain MRI scan prior to starting the next therapy (to exclude signs of PML) and to discuss the utility of CSF JCV PCR testing.</p><p></p><p class="bulletIndent2">Extended interval dosing of <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a>, which has been associated with a reduced risk of PML in observational studies, is an alternative to switching DMT for patients who seroconvert. (See <a class="local">'Extended interval dosing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a history of <strong>prior immunosuppressant use</strong> (eg, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>, or a combination) who are seropositive for anti-JCV antibodies, or who seroconvert from negative to positive during subsequent testing, the estimated risk of PML is relatively high even in the first 24 months (1:330) and increases thereafter to 1:31. Therefore, we suggest stopping <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> and transitioning to another DMT after 12 months of treatment (or sooner) for most of these patients because of the mounting risk of PML. It is unknown if prior use of newer DMTs (anti-CD20 agents, S1PR modulators, etc) confers an elevated PML risk similar to that of traditional immunosuppressants, as these agents were not yet available when the risk of prior immunosuppressants was first reported.</p><p></p><p class="bulletIndent1">Importantly, the JCV antibody status may change over time among natalizumab-treated patients with MS [<a href="#rid38">38-41</a>]. In a retrospective study of German patients with serologic follow-up over approximately eight months, conversion from anti-JCV seronegative to seropositive status occurred in 19 of 194 (10 percent), while conversion from seropositive to seronegative status occurred in 13 of 276 (5 percent) [<a href="#rid38">38</a>]. Anti-JCV antibody levels were low in both groups, suggesting that fluctuations around the cut points of the assay could lead to alternating positive and negative test results. A study of 165 patients from France reported a higher rate of seroconversion after one year of treatment with <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a>, but the study used a more sensitive anti-JCV assay, which complicates the analysis [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic assessment</strong> – Clinical vigilance and neurologic follow-up is an important aspect of monitoring for the signs and symptoms of PML. In general, MS relapses are characterized by subacute onset, typically occurring over hours to days, with eventual stabilization and resolution, and typical presentations that include diplopia, optic neuritis, and myelopathy. By contrast, PML is characterized by even slower onset over several weeks to months, progressive disease, and presentations that include aphasia, behavioral and neuropsychiatric abnormalities, cortical visual deficits, hemiparesis, and seizures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MRI monitoring</strong> – Some PML cases have been discovered prior to any symptoms, and imaging (ie, brain MRI) follow-up is very important. A baseline brain MRI scan should be obtained prior to initiating therapy with <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a>. For patients who are JCV antibody-positive, screening for PML with brain MRI more frequently (as often as every three to four months) may be advised, although practice preferences vary widely among MS experts. For patients who are negative for JCV antibodies at baseline and at one year, we suggest repeating the MRI scan every 12 months for PML monitoring  (<a class="graphic graphic_table graphicRef106610" href="/d/graphic/106610.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>New MRI lesion</strong> – Any anti-JCV seropositive patient on <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> who develops a new MRI lesion should be evaluated for the possibility of PML. Important issues are the specific characteristics of the lesion and the length of time on natalizumab. Radiologists must be informed that patients are on natalizumab and at risk for PML, as the initial lesions of PML may be indistinguishable from a new demyelinating lesion due to MS. PML lesions usually begin in the subcortical white matter of the parieto-occipital or frontal lobes but may also involve the corpus callosum, brainstem, pyramidal tracts, and cerebellum. However, the presence of punctate or confluent hyperintense T2 lesions and cortical gray matter involvement suggest PML rather than new MS-related lesions, while periventricular location and focal appearance (as opposed to a diffuse, confluent irregular, or infiltrative appearance) suggest new MS-related lesions rather than PML [<a href="#rid42">42</a>]. Cerebrospinal fluid analysis for JCV PCR DNA is mandatory in these patients, though different laboratories have different sensitivities, and the PCR may be negative in early cases of PML. (See  <a class="medical medical_review" href="/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H999310860"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>In a 2011 systematic review of trials evaluating <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> for relapsing forms of MS, pooled efficacy data from two randomized controlled trials, AFFIRM [<a href="#rid43">43</a>] and SENTINEL [<a href="#rid44">44</a>], showed that natalizumab significantly reduced the risk for having a relapse during two years of treatment (relative risk [RR] 0.57, 95% CI 0.47-0.69) [<a href="#rid45">45</a>]. In addition, natalizumab significantly reduced the risk for experiencing progression at two years (RR 0.74, 95% CI 0.62-0.89). The number needed to treat (NNT) to prevent one new exacerbation at two years was 4 (95% CI 3-5) and the NNT to prevent progression at two years was 10 (95% CI 7-23).</p><p>In the AFFIRM trial, 942 patients with relapsing MS were randomly assigned to receive either monotherapy with <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> 300 mg (n = 627) or placebo (n = 315) by IV infusion every four weeks for two years [<a href="#rid43">43</a>]. Natalizumab treatment was associated with a statistically significant 68 percent reduction in annualized relapse rate compared with placebo treatment at one year (0.26 versus 0.81), a reduction that was maintained at two years, and with a significant reduction in the cumulative probability of sustained disability progression at two years (17 versus 29 percent).</p><p>In the SENTINEL trial, 1171 patients with relapsing MS who continued to experience disease activity despite interferon beta-1a treatment were randomly assigned to also receive <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> 300 mg (n = 589) or placebo (n = 582) by IV infusion every four weeks [<a href="#rid44">44</a>]. All patients continued to receive interferon beta-1a throughout the trial. The study was stopped approximately one month early because two patients developed progressive multifocal leukoencephalopathy. Combination therapy (natalizumab plus interferon beta-1a) was associated with a statistically significant 54 percent reduction in annualized relapse rate compared with placebo at one year (0.38 versus 0.82), a difference that was maintained at two years, and with a significant reduction in the risk of sustained disability progression at two years (23 versus 29 percent).</p><p><a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">Natalizumab</a> was beneficial in all analyses of primary and secondary endpoints in both the AFFIRM and SENTINEL trials, indicating the robust nature of the results [<a href="#rid43">43,44</a>]. As an example, natalizumab treatment as monotherapy (in AFFIRM) or combination therapy (in SENTINEL) was associated with an 83 percent reduction in the number of new or enlarging hyperintense lesions on T2-weighted MRI. Finally, natalizumab treatment was associated with improved health-related quality of life compared with placebo [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H3041079556"><span class="h1">ANTI-CD20 THERAPIES</span><span class="headingEndMark"> — </span>The anti-CD20 monoclonal antibodies for MS work by targeting B cells that express CD20, which leads to depletion of circulating B cells via antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H541950819"><span class="h2">Ocrelizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">Ocrelizumab</a> is a recombinant humanized anti-CD20 (a B cell marker) monoclonal antibody that binds to a different, but overlapping, CD20 epitope than <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, another anti-B cell monoclonal antibody. It was designed to optimize B cell depletion by modification of the Fc region, which enhances antibody-dependent cell-mediated cytotoxicity and reduces complement-dependent cytotoxicity compared with rituximab; the latter has shown efficacy in small trials (see <a class="local">'Rituximab'</a> below) and has been widely used in some MS centers for years.</p><p class="headingAnchor" id="H1430544640"><span class="h3">Indications</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">Ocrelizumab</a> is indicated for relapsing forms of MS including relapsing-remitting multiple sclerosis (RRMS), clinically isolated syndromes (CIS), and active secondary progressive multiple sclerosis (SPMS); it is also indicated for primary progressive MS [<a href="#rid48">48</a>]. Ocrelizumab is <strong>contraindicated</strong> in patients with active hepatitis B virus infection and those with a history of life-threatening infusion reaction to ocrelizumab [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H2974243321"><span class="h3">Dose and administration</span><span class="headingEndMark"> — </span>The initial dose of <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">ocrelizumab</a> is a 300 mg intravenous (IV) infusion, followed two weeks later by a second 300 mg IV infusion [<a href="#rid49">49</a>]. Subsequently, ocrelizumab is given as 600 mg IV infusion every six months, beginning six months after the first 300 mg dose. The drug should be given under close medical supervision with access to medical support should severe infusion reactions develop. Premedication is recommended, with both <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> 100 mg IV (or equivalent IV or oral glucocorticoid, although sometimes this premedication is not used) approximately 30 to 60 minutes prior to each ocrelizumab infusion to reduce the frequency and severity of infusion reactions; an antipyretic (eg, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>) is often added as well. Infusions should be delayed if there is active infection until the infection resolves. Some mild infusion reactions can be treated with additional doses of methylprednisolone and/or antihistamine.</p><p class="headingAnchor" id="H3648907359"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>The most common adverse effects of <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">ocrelizumab</a> are infusion reactions, upper and lower respiratory tract infections, and skin infections [<a href="#rid49">49</a>].</p><p>In the postmarketing setting, the following infections and immune-mediated conditions have been reported in patients treated with <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">ocrelizumab</a> [<a href="#rid49">49-51</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Serious infections caused by herpes simplex virus and varicella zoster virus (VZV)</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis B reactivation</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive multifocal leukoencephalopathy (PML) that developed in patients on <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">ocrelizumab</a> who had not received <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> or prior immunomodulatory medications, and who did not have conditions resulting in compromised immune system function</p><p class="bulletIndent1"><span class="glyph">●</span>Immune-mediated colitis</p><p></p><p>There may be an increased risk of malignancy, including breast cancer, with <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">ocrelizumab</a>. In randomized trials, ocrelizumab treatment was associated with infusion reactions in 34 percent, serious infections in 1 percent, and neoplasms in 0.5 percent of patients [<a href="#rid52">52,53</a>].</p><p>Longer-term risks associated with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> use (see <a class="local">'Rituximab'</a> below) are theoretically also similar for <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">ocrelizumab</a>, and we suggest counseling patients accordingly [<a href="#rid54">54</a>].</p><p>There are no data regarding the risk of fetal harm associated with <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">ocrelizumab</a> treatment during pregnancy, but animal data suggest harm with observations of increased perinatal mortality and renal, bone marrow, and testicular toxicity [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H1915353249"><span class="h3">Screening and monitoring</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections</strong> – Patients must be screened for hepatitis B virus before starting <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">ocrelizumab</a> (see  <a class="medical medical_review" href="/d/html/3680.html" rel="external">"Hepatitis B virus: Screening and diagnosis in adults"</a>) [<a href="#rid49">49</a>]. We also screen at baseline for hepatitis C, tuberculosis, human immunodeficiency virus (HIV), and VZV, and we obtain a complete blood count with differential, lymphocyte subsets, and a metabolic panel including liver enzymes. Repeat screening for these factors depends upon individual patient characteristics, such as hepatitis risk factors, prior vaccination, and level of hepatitis B surface antibody (anti-HBs) as a positive response to vaccination. (See  <a class="medical medical_review" href="/d/html/3641.html" rel="external">"Hepatitis B virus immunization in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunoglobulin levels</strong> – Quantitative levels of immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) should be obtained at baseline; the label recommends consulting with immunology experts for patients with low immunoglobulin levels before starting <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">ocrelizumab</a> [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccination status</strong> – Patients should receive all necessary live or live-attenuated vaccines at least four weeks before starting <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">ocrelizumab</a> and non-live vaccines at least two weeks before starting ocrelizumab [<a href="#rid49">49</a>]. Live-attenuated and live vaccines are <strong>not</strong> recommended during ocrelizumab treatment or after discontinuation until B-cell repletion occurs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other concerns</strong> – Standard breast cancer screening guidelines should be followed. (see  <a class="medical medical_review" href="/d/html/7564.html" rel="external">"Screening for breast cancer: Strategies and recommendations"</a>), and patients should be monitored for immune-mediated colitis.</p><p></p><p class="headingAnchor" id="H1174082241"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Two identical randomized, controlled trials (OPERA I and OPERA II) of 821 and 825 adults with relapsing MS compared IV <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">ocrelizumab</a> (600 mg every 24 weeks) with subcutaneous interferon beta-1a (44 micrograms three times weekly) for 96 weeks [<a href="#rid52">52</a>]. All patients were pretreated with one dose of IV <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> (100 mg) before each infusion. In both trials, treatment with ocrelizumab compared with interferon beta-1a significantly reduced the annualized relapse rate (0.16 versus 0.29, absolute risk reduction [ARR] 0.13). Ocrelizumab treatment also reduced the mean number of gadolinium-enhancing lesions per MRI scan in OPERA I (0.02 versus 0.29, ARR 0.27) and in OPERA II (0.02 versus 0.42, ARR 0.40). In a prespecified pooled analysis, ocrelizumab led to a significant reduction in the proportion of subjects with confirmed disability progression at 24 weeks (6.9 versus 10.5 percent, hazard ratio 0.60, 95% CI 0.43-0.84, ARR 3.6 percent).</p><p>In the placebo-controlled ORATORIO trial, which enrolled 732 adult patients with primary progressive MS, <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">ocrelizumab</a> modestly reduced confirmed disability progression at 12 and 24 weeks. The evidence for ocrelizumab in primary progressive MS is reviewed in greater detail elsewhere. (See  <a class="medical medical_review" href="/d/html/128298.html" rel="external">"Treatment of primary progressive multiple sclerosis in adults", section on 'Ocrelizumab'</a>.)</p><p class="headingAnchor" id="H2016643606"><span class="h2">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> is a chimeric mouse-human monoclonal antibody also directed against the CD20 antigen on B lymphocytes that causes B cell reduction; its mechanism of action is similar to that of <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">ocrelizumab</a>.</p><p class="headingAnchor" id="H2156948650"><span class="h3">Indications</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> has been widely used off-label to treat relapsing forms of MS (RRMS and active SPMS) in some centers for years.</p><p class="headingAnchor" id="H2358370948"><span class="h3">Dose and administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> dosing varies among UpToDate MS experts, with the following different regimens employed [<a href="#rid55">55,56</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Induction with two 1 g infusions separated by a two-week interval, followed by 1 g infusion given every six months</p><p class="bulletIndent1"><span class="glyph">●</span>1 g infusion given every six months with a reduction in the dose and/or infusion frequency after one or two years</p><p class="bulletIndent1"><span class="glyph">●</span>500 mg infusion given every six months</p><p></p><p><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> should be given under close medical supervision with access to medical support to manage possible severe infusion reactions. Premedication is recommended using both <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> 100 or 125 mg IV (or equivalent glucocorticoid) approximately 30 minutes prior to each rituximab infusion, and with an antihistamine (eg, <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>) approximately 30 to 60 minutes prior to each rituximab infusion, to reduce the frequency and severity of infusion reactions; an antipyretic (eg, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>) can be added as well. Infusions should be delayed if there is active infection until the infection resolves.</p><p class="headingAnchor" id="H4185997412"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>Potential adverse effects include infusion reactions, hypogammaglobulinemia, infection, reactivation of hepatitis B, and neutropenia.</p><p>Rare cases of PML have been reported in patients treated with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> for other indications. However, it is unknown if rituximab increases the risk of PML, since rituximab is often used to treat patients who have an underlying risk factor for PML. (See  <a class="medical medical_review" href="/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p>A registry-based cohort study of over 6400 patients with RRMS from Sweden examined the risk of infection associated with exposure to <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a>, <a class="drug drug_general" data-topicid="16078" href="/d/drug information/16078.html" rel="external">fingolimod</a>, interferon beta, and <a class="drug drug_general" data-topicid="8490" href="/d/drug information/8490.html" rel="external">glatiramer acetate</a> [<a href="#rid54">54</a>]. Among these, treatment with rituximab was associated with the highest rate of serious infections, particularly after a few years of exposure.</p><p class="headingAnchor" id="H2922899758"><span class="h3">Screening and monitoring</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections</strong> – Patients must be screened for hepatitis B virus before starting <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (see  <a class="medical medical_review" href="/d/html/3680.html" rel="external">"Hepatitis B virus: Screening and diagnosis in adults"</a>). We also screen at baseline for hepatitis C, tuberculosis, and HIV, and we obtain a complete blood count; lymphocyte subsets; levels of IgG, IgA, and IgM; and a metabolic panel.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunoglobulin levels</strong> – Immunoglobulin levels (IgG, IgA, and IgM) should be obtained at baseline and monitored prior to each infusion cycle.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccination status</strong> – Patients should ideally receive all necessary immunizations at least four weeks prior to starting <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>. Live-attenuated vaccines are not recommended during rituximab treatment or after discontinuation of rituximab treatment until B cell repletion occurs.</p><p></p><p class="headingAnchor" id="H1478414549"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Data from randomized controlled trials supporting the effectiveness of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> for RRMS are limited but convincing, and nonrandomized studies and the positive trials for <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">ocrelizumab</a> increase confidence that rituximab is beneficial [<a href="#rid55">55</a>].</p><p>In a rater-blind trial, adult patients (n = 200) in Sweden with RRMS or CIS were randomly assigned in a 1:1 ratio to treatment with IV <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (1000 mg, followed by 500 mg every six months) or oral <a class="drug drug_general" data-topicid="88899" href="/d/drug information/88899.html" rel="external">dimethyl fumarate</a> (240 mg twice daily) [<a href="#rid57">57</a>]. At 24 months of follow-up, relapses were less frequent in the rituximab group compared with the dimethyl fumarate group (3 versus 16 percent, risk ratio [RR] 0.19, 95% CI 0.06-0.62). In an earlier randomized trial of 104 adult patients with RRMS, treatment with IV rituximab (1000 mg) given on days 1 and 15 reduced both total and new gadolinium-enhancing lesions on brain MRI at 24 weeks when compared with placebo [<a href="#rid58">58</a>]. In addition, rituximab treatment reduced the proportion of patients who had a clinical relapse by week 24.</p><p>Observational studies largely support the efficacy of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, although they are limited by the greater potential for bias and confounding compared with randomized controlled trials. In an observational study of 256 patients with stable RRMS who switched to rituximab or <a class="drug drug_general" data-topicid="16078" href="/d/drug information/16078.html" rel="external">fingolimod</a> after stopping <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">natalizumab</a> due to JC polyomavirus (JCV) antibody positivity, the rituximab group had lower rates of clinical relapse, adverse events, and treatment discontinuation compared with the fingolimod group [<a href="#rid59">59</a>]. In another observational study of 494 patients diagnosed with RRMS identified from a Swedish MS registry, rituximab treatment was associated with a lower discontinuation rate compared with other disease-modifying therapies (DMTs), including interferons, <a class="drug drug_general" data-topicid="8490" href="/d/drug information/8490.html" rel="external">glatiramer acetate</a>, <a class="drug drug_general" data-topicid="88899" href="/d/drug information/88899.html" rel="external">dimethyl fumarate</a>, fingolimod, and natalizumab [<a href="#rid60">60</a>]. Rituximab treatment was also associated with a lower rate of clinical relapses and MRI measures of disease activity compared with interferons, glatiramer acetate, and dimethyl fumarate.</p><p class="headingAnchor" id="H2667978082"><span class="h2">Ofatumumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9523" href="/d/drug information/9523.html" rel="external">Ofatumumab</a> is a human monoclonal antibody that also targets CD20 on B lymphocytes and causes selective B cell depletion.</p><p class="headingAnchor" id="H3718370771"><span class="h3">Indications</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9523" href="/d/drug information/9523.html" rel="external">Ofatumumab</a> was approved in August 2020 by the US Food and Drug Administration (FDA) for the treatment of adults with relapsing forms of MS, including CIS, RRMS, and active SPMS. Ofatumumab is <strong>contraindicated</strong> in patients with active hepatitis B virus infection.</p><p class="headingAnchor" id="H1673448789"><span class="h3">Dose and administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9523" href="/d/drug information/9523.html" rel="external">Ofatumumab</a> is given by subcutaneous injection, starting with 20 mg administered at weeks zero, one, and two. Subsequently, the dose is 20 mg per month starting at week four [<a href="#rid61">61</a>]. Administration should be delayed in patients with active infection until the infection resolves.</p><p class="headingAnchor" id="H290245981"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>The most common adverse effects observed with <a class="drug drug_general" data-topicid="9523" href="/d/drug information/9523.html" rel="external">ofatumumab</a> are upper respiratory tract infection, headache, injection-related reactions, and local injection site reactions [<a href="#rid61">61</a>]. The potential for reduction in immunoglobulins may increase the risk of recurrent infections or opportunistic infections.</p><p>Animal data suggest a risk of fetal harm. The label recommends use of an effective method of contraception during <a class="drug drug_general" data-topicid="9523" href="/d/drug information/9523.html" rel="external">ofatumumab</a> treatment and for six months after discontinuation [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H2100360127"><span class="h3">Screening and monitoring</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections</strong> – Before the first dose of <a class="drug drug_general" data-topicid="9523" href="/d/drug information/9523.html" rel="external">ofatumumab</a>, patients should be screened for hepatitis B virus. We also screen at baseline for hepatitis C, tuberculosis, HIV, and VZV, and we obtain a complete blood count with differential, lymphocyte subsets, and a metabolic panel including liver enzymes. Repeat screening for these factors depends upon individual patient characteristics, such as hepatitis risk factors, prior vaccination, and level of anti-HBs as a positive response to vaccination. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunoglobulin levels</strong> – Quantitative serum levels of IgG, IgA, and IgM should be obtained at baseline and monitored during treatment and after discontinuation of <a class="drug drug_general" data-topicid="9523" href="/d/drug information/9523.html" rel="external">ofatumumab</a> treatment until B cell repletion occurs [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccination status</strong> – Patients should receive all recommended immunizations at least four weeks before starting <a class="drug drug_general" data-topicid="9523" href="/d/drug information/9523.html" rel="external">ofatumumab</a>. Live or live-attenuated vaccines are not recommended during treatment and after stopping treatment until B cell repletion occurs.</p><p></p><p class="headingAnchor" id="H782538787"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Efficacy of <a class="drug drug_general" data-topicid="9523" href="/d/drug information/9523.html" rel="external">ofatumumab</a> was established in two controlled trials (ASCLEPIOS I and II) of identical design that enrolled a combined total of over 1800 adults with relapsing MS [<a href="#rid62">62</a>]. Patients were randomly assigned in a 1:1 ratio to treatment with subcutaneous ofatumumab and oral placebo or oral <a class="drug drug_general" data-topicid="86616" href="/d/drug information/86616.html" rel="external">teriflunomide</a> and subcutaneous placebo for up to 30 months. At a median follow-up of 1.6 years, ofatumumab compared with teriflunomide reduced the annualized relapse rate in ASCLEPIOS I (0.11 versus 0.22, ARR -0.11, 95% CI -0.16 to -0.06) and ASCLEPIOS II (0.10 versus 0.25, ARR -0.15, 95% CI -0.20 to -0.09). In pooled data from the two trials, ofatumumab reduced the number of patients with disability worsening confirmed at six months (8.1 percent, versus 12.0 with teriflunomide, hazard ratio 0.68, 95% CI 0.50-0.92, ARR 4.1 percent). In both trials, ofatumumab reduced the mean number of gadolinium-enhancing lesions per T1-weighted MRI scan and the annualized rate of new or enlarged lesions on T2-weighted MRI.</p><p class="headingAnchor" id="H2297944179"><span class="h2">Ublituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="140396" href="/d/drug information/140396.html" rel="external">Ublituximab</a> is a recombinant mouse-human chimeric monoclonal antibody that binds to a CD20 epitope distinct from those targeted by <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">ocrelizumab</a>, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, and <a class="drug drug_general" data-topicid="9523" href="/d/drug information/9523.html" rel="external">ofatumumab</a>. Ublituximab was glycoengineered with a low sugar content in its Fc segment to achieve a high affinity for Fc gamma RIIIa (CD16) receptors [<a href="#rid63">63</a>]. This enhances its ability to activate natural killer cell-mediated antibody-dependent cellular cytotoxicity, leading to B cell depletion.</p><p class="headingAnchor" id="H2464066767"><span class="h3">Indications</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="140396" href="/d/drug information/140396.html" rel="external">Ublituximab</a> was approved by the FDA in December 2022 for the treatment of adults with relapsing forms of MS, including CIS, RRMS, and active SPMS [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H3429602102"><span class="h3">Dose and administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="140396" href="/d/drug information/140396.html" rel="external">Ublituximab</a> is administered intravenously [<a href="#rid64">64</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>150 mg for the first infusion</p><p class="bulletIndent1"><span class="glyph">●</span>450 mg for the second infusion, approximately two weeks after the first</p><p class="bulletIndent1"><span class="glyph">●</span>450 mg for subsequent infusions beginning 24 weeks after the first infusion and every 24 weeks thereafter</p><p></p><p>Premedication with <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> 100 mg IV (or an equivalent glucocorticoid) and an antihistamine (eg, <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>) is recommended before each dose. Patients should be monitored during infusions and for at least one hour after completing the first two infusions. Thereafter, postinfusion monitoring is at the discretion of the treating clinician.</p><p>Administration should be delayed in patients with active infection until the infection resolves.</p><p class="headingAnchor" id="H1369726610"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>The most common adverse effects of <a class="drug drug_general" data-topicid="140396" href="/d/drug information/140396.html" rel="external">ublituximab</a> seen in clinical trials are infusion reactions, with an incidence of approximately 50 percent, and upper respiratory tract infections, with an incidence of approximately 45 percent [<a href="#rid64">64</a>]. Other adverse effects include:</p><p class="bulletIndent1"><span class="glyph">●</span>Potentially life-threatening bacterial and viral infections</p><p class="bulletIndent1"><span class="glyph">●</span>Reduction in immunoglobulins</p><p class="bulletIndent1"><span class="glyph">●</span>Potential for fetal harm</p><p></p><p><a class="drug drug_general" data-topicid="140396" href="/d/drug information/140396.html" rel="external">Ublituximab</a> is contraindicated for patients with active hepatitis B virus infection and for those with prior life-threatening infusion reaction to ublituximab [<a href="#rid64">64</a>]. The label recommends use of an effective method of contraception during ublituximab treatment and for six months after discontinuation.</p><p class="headingAnchor" id="H2236583432"><span class="h3">Screening and monitoring</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections</strong> – Patients should be screened at baseline for hepatitis B virus; we also screen for hepatitis C, tuberculosis, HIV, and VZV, and we obtain a complete blood count, lymphocyte subsets, and a metabolic panel. Repeat screening for these factors depends upon individual patient characteristics, such as hepatitis risk factors, prior vaccination, and level of anti-HBs as a positive response to vaccination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunoglobulin levels</strong> – Quantitative levels of IgG, IgA, and IgM should be obtained at baseline; the label recommends consulting with immunology experts for patients with low immunoglobulin levels before starting <a class="drug drug_general" data-topicid="140396" href="/d/drug information/140396.html" rel="external">ublituximab</a> [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccination status</strong> – As with other B cell depleting agents, patients should receive all recommended immunizations at least four weeks before starting <a class="drug drug_general" data-topicid="140396" href="/d/drug information/140396.html" rel="external">ublituximab</a>. Live or live-attenuated vaccines are not recommended during treatment and after stopping treatment until B cell repletion occurs.</p><p></p><p class="headingAnchor" id="H1630667382"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>The efficacy of <a class="drug drug_general" data-topicid="140396" href="/d/drug information/140396.html" rel="external">ublituximab</a> for patients with relapsing MS was demonstrated in two identical randomized trials, ULTIMATE I (n = 549) and ULTIMATE II (n = 545) [<a href="#rid65">65</a>]. Patients in these trials were randomly assigned in a 1:1 ratio to IV ublituximab (150 mg on day one, followed by 450 mg on day 15 and at weeks 24, 48, and 72) plus oral placebo, or to oral <a class="drug drug_general" data-topicid="86616" href="/d/drug information/86616.html" rel="external">teriflunomide</a> (14 mg daily) plus IV placebo. At a median follow-up of 95 weeks, the annualized relapse rate was lower with ublituximab compared with teriflunomide in ULTIMATE I (0.08 versus 0.19; rate ratio [RR] 0.41, 95% CI 0.27-0.62) and ULTIMATE II (0.09 versus 0.18; RR 0.51, 95% CI 0.33-0.78). The mean number of gadolinium-enhancing brain lesions on MRI was also lower with ublituximab compared with teriflunomide in ULTIMATE I (0.02 versus 0.49; RR 0.03, 95% CI 0.02-0.06) and ULTIMATE II (0.01 versus 0.25; RR 0.04, 95% CI 0.02-0.06).</p><p>In a pooled analysis of the two trials, worsening of disability at 12 weeks was similar with <a class="drug drug_general" data-topicid="140396" href="/d/drug information/140396.html" rel="external">ublituximab</a> and <a class="drug drug_general" data-topicid="86616" href="/d/drug information/86616.html" rel="external">teriflunomide</a> (5.2 versus 5.9 percent, hazard ratio 0.84; 95% CI 0.50-1.41) [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H595682805"><span class="h1">ANTI-CD52 THERAPY</span></p><p class="headingAnchor" id="H3393755797"><span class="h2">Alemtuzumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">Alemtuzumab</a> is a humanized monoclonal antibody that causes depletion of CD52-expressing T cells, B cells, natural killer cells, and monocytes [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H3220927440"><span class="h3">Indications</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">Alemtuzumab</a> is indicated for the treatment of relapsing forms of MS, including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS). Because of its safety profile (see <a class="local">'Adverse effects'</a> below), alemtuzumab is <strong>not</strong> recommended for the treatment of clinically isolated syndromes (CIS).</p><p><a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">Alemtuzumab</a> is generally reserved in the United States for patients with highly active RRMS who have had an inadequate response to two or more disease-modifying therapies (DMTs), or where other DMTs cannot be used. Furthermore, the European Medicines Agency (EMA) recommends that alemtuzumab should only be used for the treatment of RRMS if the disease is highly active despite treatment with at least one DMT or if the disease is worsening rapidly [<a href="#rid67">67</a>].</p><p><a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">Alemtuzumab</a> is <strong>contraindicated</strong> in patients with HIV infection, active infection, or known hypersensitivity to alemtuzumab [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H964689586"><span class="h3">Dose and administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">Alemtuzumab</a> is administered via IV infusion at 12 mg daily for five consecutive days (total 60 mg) at the start of treatment, followed 12 months later by 12 mg daily for three consecutive days (total 36 mg) [<a href="#rid68">68</a>]. Subsequent treatments (12 mg daily for three consecutive days, total dose 36 mg) are given as needed at least 12 months after the last dose of a previous treatment course.</p><p>Premedication with glucocorticoids (1 g of <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a>) for the first three days of therapy is indicated. Infusions should be administered in a medical setting capable of managing anaphylaxis, serious infusion reactions, and myocardial, cerebrovascular, or pulmonary adverse reactions, and patients should be observed for at least two hours after each infusion.</p><p>Antiviral prophylaxis for herpetic viral infections (eg, oral <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> 200 mg given twice daily) is recommended, starting on the first day of each treatment course and continuing for at least two months following treatment with <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> or until the CD4+ lymphocyte count is at least 200 cells per microliter, whichever occurs later [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H414754483"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>The main side effects of <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> are infusion reactions, infections, and autoimmune disorders [<a href="#rid69">69-72</a>]. Infusion reactions occur in approximately 90 percent of patients and are characterized by headache, rash, nausea, and fever. Infections, though generally not severe, were observed in two-thirds or more of the patients treated with alemtuzumab. Herpes viral infections occurred in 16 to 18 percent, leading to a change in the protocol of the in-progress CARE-MS trials with the addition of prophylactic <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> treatment during alemtuzumab infusion and for 28 days after infusion [<a href="#rid70">70,71</a>]. Thyroid autoimmunity was seen in 16 to 18 percent of patients at two years after alemtuzumab treatment [<a href="#rid70">70,71</a>], and in 30 percent with longer follow-up [<a href="#rid72">72</a>]. Immune thrombocytopenia (ITP) developed in 1 percent of patients at two years [<a href="#rid70">70,71</a>] and in 3 percent at three years [<a href="#rid69">69,72</a>]. This included one patient who suffered a fatal intracerebral hemorrhage in a phase II study of alemtuzumab. All subsequent ITP cases were detected through a monitoring program and successfully treated [<a href="#rid73">73</a>].</p><p>The prescribing label warns of an increased risk of autoimmunity (ITP, thrombotic thrombocytopenic purpura [TTP], antiglomerular basement membrane disease, autoimmune encephalitis), infusion reactions, thyroid disorders, hemophagocytic lymphohistiocytosis, adult-onset Still disease, acquired hemophilia A, infections, and malignancies (thyroid cancer, melanoma, lymphoproliferative disorders) [<a href="#rid68">68</a>].</p><p>Other reports described three cases of acute acalculous cholecystitis [<a href="#rid74">74</a>] and two cases of neutropenia [<a href="#rid75">75</a>] during treatment with <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> for RRMS. Announcements from the US Food and Drug Administration (FDA) and EMA have warned of cases of ischemic stroke, hemorrhagic stroke, arterial dissection, and myocardial infarction that occurred shortly after starting treatment with alemtuzumab [<a href="#rid67">67,76,77</a>].</p><p class="headingAnchor" id="H643548288"><span class="h3">Screening and monitoring</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">Alemtuzumab</a> therapy requires monitoring (for infusion reactions, symptoms of ITP, and symptoms of nephropathy) and prophylaxis for herpes virus infections (oral <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> 200 mg twice daily) during treatment and continuing for at least two months after completion of a treatment course, or until the CD4+ count is &gt;200 cells/microL, whichever occurs later [<a href="#rid68">68</a>]. Prolonged surveillance (for 48 months after the last dose) for bone marrow suppression, infections, and autoimmune disorders such as ITP is also necessary. Patients should be educated about the symptoms of ITP and should report them immediately if they develop.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections</strong> – Patients should be screened for tuberculosis and advised to avoid potential sources of <em>Listeria monocytogenes</em>. (See  <a class="medical medical_review" href="/d/html/1303.html" rel="external">"Treatment and prevention of Listeria monocytogenes infection", section on 'Prevention of foodborne infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccination status</strong> – Necessary immunizations must be completed at least six weeks before the start of treatment with <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> [<a href="#rid68">68</a>]. Patients without a history of varicella zoster virus (VZV) infection or vaccination for VZV should be tested for antibodies to VZV. Vaccination for VZV should be considered for patients who are antibody-negative, postponing alemtuzumab treatment for six weeks after VZV vaccination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory tests</strong> – To monitor for early signs of potentially serious adverse events, laboratory testing is recommended at baseline and periodically thereafter until 48 months after the last treatment course of <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> for the following [<a href="#rid68">68</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urine protein to creatinine ratio prior to initiation of treatment</p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count with differential prior to treatment and at monthly intervals thereafter</p><p class="bulletIndent2"><span class="glyph">•</span>Serum creatinine levels prior to treatment and at monthly intervals thereafter</p><p class="bulletIndent2"><span class="glyph">•</span>Urinalysis with urine cell counts prior to treatment and at monthly intervals thereafter</p><p class="bulletIndent2"><span class="glyph">•</span>Thyroid function testing (eg, thyroid-stimulating hormone [TSH] level) prior to treatment and every three months thereafter</p><p class="bulletIndent2"><span class="glyph">•</span>Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin levels prior to initiation and periodically thereafter</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignancy</strong> – Baseline and yearly skin examination are recommended to monitor for melanoma [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk management program</strong> – Treatment with <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> in the United States requires special registration through a restricted distribution program (the LEMTRADA Risk Evaluation and Mitigation Strategy or REMS) for both the center and patient to ensure adequate follow-up [<a href="#rid78">78</a>].</p><p></p><p class="headingAnchor" id="H3726155387"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Data from randomized controlled trials show that <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> is more effective than interferon beta-1a for reducing the relapse rate in RRMS [<a href="#rid79">79</a>]. This benefit is associated with a small increased risk of potentially serious infections and autoimmune disorders, including ITP [<a href="#rid69">69-71</a>].</p><p>CARE-MS I was a rater-blind trial that evaluated over 550 adults with RRMS, low disability levels, and no prior DMT [<a href="#rid70">70</a>]. Subjects were randomly assigned to either <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> or subcutaneous interferon beta-1a (44 mcg three times per week) in a 2:1 ratio. Alemtuzumab was infused intravenously at 12 mg daily for five days at the start of treatment and for three days at 12 months. At two years, alemtuzumab reduced the proportion of patients with any relapse (22 percent, versus 40 percent for interferon beta-1a, rate ratio 0.45, 95% CI 0.23-0.63) and the annualized relapse rate (0.18 versus 0.39). However, there was no significant difference between groups for sustained accumulation of disability (8 versus 11 percent). Imaging outcomes were mixed; there was no significant difference between groups for median change in volume of T2-hyperintense brain lesions, but the alemtuzumab group had fewer new or enlarging T2-hyperintense lesions and fewer gadolinium-enhancing lesions.</p><p>The similar CARE-MS II trial evaluated nearly 800 adults with RRMS and at least one relapse while on treatment with interferon beta-1a or <a class="drug drug_general" data-topicid="8490" href="/d/drug information/8490.html" rel="external">glatiramer acetate</a> [<a href="#rid71">71</a>]. At two years, <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> reduced the proportion of patients with any relapse (35 percent, versus 53 percent for interferon beta-1a, rate ratio 0.51, 95% CI 0.39-0.65) and the annualized relapse rate (0.26 versus 0.52). Unlike CARE-MS I, the alemtuzumab group in CARE-MS II had a significantly lower rate of sustained accumulation of disability (13 versus 20 percent, hazard ratio 0.58, 95% CI 0.38-0.87). Like CARE-MS I, the imaging outcomes in CARE-MS II showed no significant difference between groups for median change in volume of T2-hyperintense brain lesions, but the alemtuzumab group had significantly fewer new or enlarging T2-hyperintense lesions, and fewer gadolinium-enhancing lesions. Notably, the CARE-MS II trial design may have magnified the treatment effect of alemtuzumab, as some patients were randomly assigned to the same treatment (interferon beta-1a) on which they had disease activity prior to enrollment. Modern treatment paradigms usually do not continue a therapy that has been associated with breakthrough disease.</p><p class="headingAnchor" id="H1410814085"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117065.html" rel="external">"Society guideline links: Multiple sclerosis and related disorders"</a>.)</p><p class="headingAnchor" id="H1092051160"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of monoclonal antibody treatment</strong> – Disease-modifying therapies (DMTs) for multiple sclerosis (MS) include several categories of medications. Monoclonal antibody DMTs are highly efficacious and may be preferred for patients with more active disease and for those who place a high value on efficacy and are risk-tolerant. However, serious safety issues, including infections, are possible adverse effects of several of these medications. The choice of DMT for patients with MS should be individualized according to disease activity and patient values and preferences  (<a class="graphic graphic_algorithm graphicRef102519" href="/d/graphic/102519.html" rel="external">algorithm 1</a>). (See <a class="local">'Choosing therapy'</a> above.)</p><p></p><p class="bulletIndent1">The use of DMT for specific clinical situations is discussed in detail elsewhere:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/1691.html" rel="external">"Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/1687.html" rel="external">"Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/129095.html" rel="external">"Indications for switching or stopping disease-modifying therapy for multiple sclerosis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/1686.html" rel="external">"Treatment of secondary progressive multiple sclerosis in adults"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/128298.html" rel="external">"Treatment of primary progressive multiple sclerosis in adults"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/135221.html" rel="external">"Multiple sclerosis: Pregnancy planning"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/138599.html" rel="external">"Multiple sclerosis: Pregnancy and postpartum care"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natalizumab</strong> – <a class="drug drug_general" data-topicid="10252" href="/d/drug information/10252.html" rel="external">Natalizumab</a>, an integrin receptor antagonist, is indicated as monotherapy for the treatment of relapsing forms of MS, including clinically isolated syndromes (CIS), relapsing-remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis (SPMS). It is administered by intravenous (IV) infusion every four weeks. Natalizumab treatment is associated with the risk of opportunistic infections, including progressive multifocal leukoencephalopathy (PML), and hepatoxicity. The risk of PML is related to the JC polyomavirus (JCV) antibody level. Screening and monitoring recommendations, including JCV antibody status, and PML surveillance, are discussed above. (See <a class="local">'Natalizumab'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ocrelizumab</strong> – <a class="drug drug_general" data-topicid="112485" href="/d/drug information/112485.html" rel="external">Ocrelizumab</a> is a recombinant humanized anti-CD20 monoclonal antibody that depletes B cells. It is indicated for relapsing forms of MS (CIS, RRMS, active SPMS) and for primary progressive MS. It is given by IV infusion as described in detail above. Potential serious adverse effects include infections, infusion reactions, immune-mediated colitis, hypogammaglobulinemia, and an increased risk of malignancy. Screening and monitoring recommendations are discussed above. (See <a class="local">'Ocrelizumab'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rituximab</strong> – <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> is a chimeric mouse-human anti-CD20 monoclonal antibody that causes B cell reduction. It is widely used off-label to treat relapsing or active forms of MS. It is given by IV infusion as described in detail above. Potential adverse effects include infections, infusion reactions, reactivation of hepatitis B, and hypogammaglobulinemia. Screening and monitoring recommendations are discussed above. (See <a class="local">'Rituximab'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ofatumumab</strong> – <a class="drug drug_general" data-topicid="9523" href="/d/drug information/9523.html" rel="external">Ofatumumab</a> is a human monoclonal antibody that also targets CD20 on B lymphocytes and causes selective B cell depletion. It is indicated for relapsing forms of MS (CIS, RRMS, and active SPMS). It is administered by subcutaneous injection, with dosing as described above. Potential adverse effects include infections, infusion reactions, reactivation of hepatitis B, and hypogammaglobulinemia. Screening and monitoring recommendations are discussed above. (See <a class="local">'Ofatumumab'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ublituximab</strong> – <a class="drug drug_general" data-topicid="140396" href="/d/drug information/140396.html" rel="external">Ublituximab</a> is a chimeric monoclonal antibody with a glycoengineered Fc segment (to enhance antibody-dependent cell-mediated cytotoxicity) that targets a different CD20 epitope than the other anti-CD20 monoclonal antibodies and causes B cell depletion. It is indicated for relapsing forms of MS (CIS, RRMS, and active SPMS). It is given by IV infusion, with premedication and dosing as described above. Potential adverse effects include infections, infusion reactions, reactivation of hepatitis B, and hypogammaglobulinemia. Screening and monitoring recommendations are discussed above. (See <a class="local">'Ublituximab'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alemtuzumab</strong> – <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">Alemtuzumab</a> is a humanized monoclonal antibody that causes depletion of CD52-expressing T cells, B cells, natural killer cells, and monocytes. It is indicated for the treatment of relapsing MS, including RRMS and active SPMS. However, alemtuzumab is <strong>not</strong> recommended for the treatment of CIS because of its safety profile. Alemtuzumab is given by IV infusion, with premedication and dosing described above. Potential adverse effects include infections, thyroid disorders, immune thrombocytopenic purpura, thrombotic thrombocytopenic purpura, nephropathy, autoimmune encephalitis, adult-onset Still disease, acquired hemophilia A, autoimmune hepatitis, hemophagocytic lymphohistiocytosis, infusion reactions, ischemic and hemorrhagic stroke, myocardial ischemia, and malignancies. Screening and monitoring recommendations are discussed above. (See <a class="local">'Alemtuzumab'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Niino M, Bodner C, Simard ML, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006; 59:748.</a></li><li><a class="nounderline abstract_t">Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006; 59:743.</a></li><li class="breakAll">Tyruko (natalizumab-sztn) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761322s000lbl.pdf (Accessed on October 03, 2023).</li><li><a class="nounderline abstract_t">Kappos L, Bates D, Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007; 6:431.</a></li><li><a class="nounderline abstract_t">Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007; 356:2622.</a></li><li><a class="nounderline abstract_t">Zhovtis Ryerson L, Frohman TC, Foley J, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016; 87:885.</a></li><li><a class="nounderline abstract_t">van Kempen ZLE, Hoogervorst ELJ, Wattjes MP, et al. Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial. Neurology 2020; 95:e745.</a></li><li><a class="nounderline abstract_t">Ryerson LZ, Foley J, Chang I, et al. Natalizumab extended interval dosing (EID) is associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) than every-4-week (Q4W) dosing: Updated analysis of the TOUCH Prescribing Program database. Neurology 2020; 94 (15 Suppl):1988.</a></li><li><a class="nounderline abstract_t">Foley J, Xiong K, Hoyt T, et al. Serum neurofilament light (sNfL) levels in patients with relapsing-remitting multiple sclerosis (RRMS) switching from natalizumab every-4-week (Q4W) dosing to extended interval dosing (EID). Neurology 2020; 94 (15 Suppl):2013.</a></li><li><a class="nounderline abstract_t">Ryerson LZ, Foley J, Chang I, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 2019; 93:e1452.</a></li><li><a class="nounderline abstract_t">Chisari CG, Grimaldi LM, Salemi G, et al. Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2020; 91:1297.</a></li><li><a class="nounderline abstract_t">Ryerson LZ, Naismith RT, Krupp LB, et al. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS. Mult Scler Relat Disord 2022; 58:103480.</a></li><li><a class="nounderline abstract_t">Foley JF, Defer G, Ryerson LZ, et al. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol 2022; 21:608.</a></li><li><a class="nounderline abstract_t">Johnsson M, Farman HH, Blennow K, et al. No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab. Mult Scler 2022; 28:2070.</a></li><li><a class="nounderline abstract_t">Butzkueven H, Kappos L, Pellegrini F, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry 2014; 85:1190.</a></li><li class="breakAll">Tysabri (natalizumab) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125104s973s975lbl.pdf (Accessed on December 21, 2021).</li><li><a class="nounderline abstract_t">Kwiatkowski A, Gallois J, Bilbault N, et al. Herpes encephalitis during natalizumab treatment in multiple sclerosis. Mult Scler 2012; 18:909.</a></li><li><a class="nounderline abstract_t">Dahdaleh D, Altmann DM, Malik O, Nicholas RS. Breathlessness, night sweats, and weight loss on natalizumab. Lancet 2012; 380:726.</a></li><li class="breakAll">US Food and Drug Administration. Tysabri (natalizumab) Feb 2008. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm110608.htm (Accessed on October 28, 2010).</li><li><a class="nounderline abstract_t">Bezabeh S, Flowers CM, Kortepeter C, Avigan M. Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol Ther 2010; 31:1028.</a></li><li><a class="nounderline abstract_t">Stefoski D, Foley J, Roman C, et al. Real-world outcomes and treatments for natalizumab-associated progressive multifocal leukoencephalopathy. Int J Mult Scler Care 2023; 25:4.</a></li><li><a class="nounderline abstract_t">Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011; 10:745.</a></li><li><a class="nounderline abstract_t">Fox RJ, Rudick RA. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology 2012; 78:436.</a></li><li><a class="nounderline abstract_t">Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366:1870.</a></li><li><a class="nounderline abstract_t">McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 2016; 87:117.</a></li><li><a class="nounderline abstract_t">Berger JR, Fox RJ. Reassessing the risk of natalizumab-associated PML. J Neurovirol 2016; 22:533.</a></li><li><a class="nounderline abstract_t">Gagne Brosseau MS, Stobbe G, Wundes A. Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay. Neurology 2016; 86:484.</a></li><li class="breakAll">Tysabri® (natalizumab): PML in patients receiving Tysabri (USA Tysabri PML Update). https://medinfo.biogen.com (Accessed on November 02, 2017).</li><li><a class="nounderline abstract_t">Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007; 69:1391.</a></li><li class="breakAll">US Food and Drug Administration. Tysabri risk minimization action plan: summary of TOUCH. www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM107197.pdf (Accessed on February 09, 2016).</li><li><a class="nounderline abstract_t">Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014; 76:802.</a></li><li><a class="nounderline abstract_t">Schwab N, Schneider-Hohendorf T, Melzer N, et al. Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification. Neurology 2017; 88:1197.</a></li><li class="breakAll">Tysabri (natalizumab): PML incidence in patients receiving Tysabri. https://medinfo.biogen.com/medinfo (Accessed on June 10, 2020).</li><li><a class="nounderline abstract_t">Baroncini D, Ghezzi A, Guaschino C, et al. Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study. Neurol Sci 2022; 43:6415.</a></li><li><a class="nounderline abstract_t">Pato Pato A, Costa Arpín E, Rodríguez Regal A, et al. Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the "no evidence of disease activity" parameter. Neurologia (Engl Ed) 2021; 36:346.</a></li><li><a class="nounderline abstract_t">Guger M, Enzinger C, Leutmezer F, et al. Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry. J Neurol 2021; 268:4303.</a></li><li><a class="nounderline abstract_t">Gaughan M, Gilligan M, Patterson I, et al. Longitudinal stability of JCV antibody index in Natalizumab treated people with multiple sclerosis. Mult Scler Relat Disord 2022; 68:104251.</a></li><li><a class="nounderline abstract_t">Trampe AK, Hemmelmann C, Stroet A, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 2012; 78:1736.</a></li><li><a class="nounderline abstract_t">Outteryck O, Zéphir H, Salleron J, et al. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler 2014; 20:822.</a></li><li><a class="nounderline abstract_t">Schwab N, Schneider-Hohendorf T, Pignolet B, et al. Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurol Neuroimmunol Neuroinflamm 2016; 3:e195.</a></li><li><a class="nounderline abstract_t">Raffel J, Gafson AR, Malik O, Nicholas R. Anti-JC virus antibody titres increase over time with natalizumab treatment. Mult Scler 2015; 21:1833.</a></li><li><a class="nounderline abstract_t">Wijburg MT, Witte BI, Vennegoor A, et al. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. J Neurol Neurosurg Psychiatry 2016; 87:1138.</a></li><li><a class="nounderline abstract_t">Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899.</a></li><li><a class="nounderline abstract_t">Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354:911.</a></li><li><a class="nounderline abstract_t">Pucci E, Giuliani G, Solari A, et al. Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev 2011; :CD007621.</a></li><li><a class="nounderline abstract_t">Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007; 62:335.</a></li><li><a class="nounderline abstract_t">Krajnc N, Bsteh G, Berger T, et al. Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management. Neurotherapeutics 2022; 19:753.</a></li><li class="breakAll">FDA approves new drug to treat multiple sclerosis. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm549325.htm (Accessed on March 30, 2017).</li><li class="breakAll">Ocrevus (ocrelizumab) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761053s029s030lbl.pdf (Accessed on August 05, 2022).</li><li><a class="nounderline abstract_t">Patel A, Sul J, Gordon ML, et al. Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy. JAMA Neurol 2021; 78:736.</a></li><li><a class="nounderline abstract_t">Ciardi MR, Iannetta M, Zingaropoli MA, et al. Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis. Open Forum Infect Dis 2019; 6:ofy356.</a></li><li><a class="nounderline abstract_t">Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017; 376:221.</a></li><li><a class="nounderline abstract_t">Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011; 378:1779.</a></li><li><a class="nounderline abstract_t">Luna G, Alping P, Burman J, et al. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol 2020; 77:184.</a></li><li><a class="nounderline abstract_t">Whittam DH, Tallantyre EC, Jolles S, et al. Rituximab in neurological disease: principles, evidence and practice. Pract Neurol 2019; 19:5.</a></li><li><a class="nounderline abstract_t">Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology 2016; 87:2074.</a></li><li><a class="nounderline abstract_t">Svenningsson A, Frisell T, Burman J, et al. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol 2022; 21:693.</a></li><li><a class="nounderline abstract_t">Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358:676.</a></li><li><a class="nounderline abstract_t">Alping P, Frisell T, Novakova L, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 2016; 79:950.</a></li><li><a class="nounderline abstract_t">Granqvist M, Boremalm M, Poorghobad A, et al. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis. JAMA Neurol 2018; 75:320.</a></li><li class="breakAll">Kesimpta (ofatumumab) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125326s075lbl.pdf (Accessed on October 26, 2023).</li><li><a class="nounderline abstract_t">Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med 2020; 383:546.</a></li><li><a class="nounderline abstract_t">de Romeuf C, Dutertre CA, Le Garff-Tavernier M, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol 2008; 140:635.</a></li><li class="breakAll">Briumvi (ublituximab-xiiy) injection, for intravenous use; labelling - package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761238s000lbl.pdf (Accessed on January 03, 2023).</li><li><a class="nounderline abstract_t">Steinman L, Fox E, Hartung HP, et al. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med 2022; 387:704.</a></li><li><a class="nounderline abstract_t">Ruck T, Bittner S, Wiendl H, Meuth SG. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. Int J Mol Sci 2015; 16:16414.</a></li><li class="breakAll">European Medicines Agency. Measures to minimise risk of serious side effects of multiple sclerosis medicine Lemtrada. https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis_en-0.pdf (Accessed on May 05, 2020).</li><li class="breakAll">Lemtrada (alemtuzumab) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/103948s5185lbl.pdf (Accessed on June 17, 2022).</li><li><a class="nounderline abstract_t">CAMMS223 Trial Investigators, Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359:1786.</a></li><li><a class="nounderline abstract_t">Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380:1819.</a></li><li><a class="nounderline abstract_t">Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380:1829.</a></li><li><a class="nounderline abstract_t">Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012; 78:1069.</a></li><li><a class="nounderline abstract_t">Cuker A, Stasi R, Palmer J, et al. Successful detection and management of immune thrombocytopenia in alemtuzumab-treated patients with active relapsing-remitting multiple sclerosis (P2.198). Neurology 2014; 82:2.198.</a></li><li><a class="nounderline abstract_t">Pfeuffer S, Beuker C, Ruck T, et al. Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS. Neurology 2016; 87:2380.</a></li><li><a class="nounderline abstract_t">Gaitán MI, Ysrraelit MC, Correale J. Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab. JAMA Neurol 2017; 74:1143.</a></li><li class="breakAll">FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab). https://www.fda.gov/Drugs/DrugSafety/ucm624247.htm (Accessed on November 29, 2018).</li><li><a class="nounderline abstract_t">Azevedo CJ, Kutz C, Dix A, et al. Intracerebral haemorrhage during alemtuzumab administration. Lancet Neurol 2019; 18:329.</a></li><li class="breakAll">LEMTRADA REMS (Risk Evaluation and Mitigation Strategy) program. www.lemtradarems.com (Accessed on July 28, 2020).</li><li><a class="nounderline abstract_t">Zhang J, Shi S, Zhang Y, et al. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2017; 11:CD010968.</a></li></ol></div><div id="topicVersionRevision">Topic 143122 Version 3.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16634035" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Natalizumab effects on immune cell responses in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16634029" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Immune surveillance in multiple sclerosis patients treated with natalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16634029" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Immune surveillance in multiple sclerosis patients treated with natalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17434098" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17582072" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Natalizumab for multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26917698" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Extended interval dosing of natalizumab in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32690785" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Natalizumab extended interval dosing (EID) is associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) than every-4-week (Q4W) dosing: Updated analysis of the TOUCH Prescribing Program database</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Serum neurofilament light (sNfL) levels in patients with relapsing-remitting multiple sclerosis (RRMS) switching from natalizumab every-4-week (Q4W) dosing to extended interval dosing (EID)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31515290" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33055141" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35051898" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35483387" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35856574" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24532785" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24532785" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22048950" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Herpes encephalitis during natalizumab treatment in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22920745" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Breathlessness, night sweats, and weight loss on natalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22920745" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Breathlessness, night sweats, and weight loss on natalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20163378" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinically significant liver injury in patients treated with natalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Real-world outcomes and treatments for natalizumab-associated progressive multifocal leukoencephalopathy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21777829" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22282644" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Risk stratification and patient counseling for natalizumab in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22591293" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Risk of natalizumab-associated progressive multifocal leukoencephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26492930" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26843383" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Reassessing the risk of natalizumab-associated PML.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26740679" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26740679" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17761550" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17761550" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25273271" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28228564" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28228564" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35781765" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34714232" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the "no evidence of disease activity" parameter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33890167" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36283323" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Longitudinal stability of JCV antibody index in Natalizumab treated people with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22592369" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24072722" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26848486" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26449743" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Anti-JC virus antibody titres increase over time with natalizumab treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27530808" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16510744" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16510745" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21975773" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Natalizumab for relapsing remitting multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17696126" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Health-related quality of life in multiple sclerosis: effects of natalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35378683" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35378683" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35378683" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33724354" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30697576" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28002679" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22047971" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31589278" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30498056" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Rituximab in neurological disease: principles, evidence and practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27760868" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35841908" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18272891" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27038238" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29309484" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29309484" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32757523" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Ofatumumab versus Teriflunomide in Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18302712" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18302712" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36001711" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26204829" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26204829" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26204829" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18946064" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23122652" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23122650" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22442431" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Alemtuzumab more effective than interferonβ-1a at 5-year follow-up of CAMMS223 clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Successful detection and management of immune thrombocytopenia in alemtuzumab-treated patients with active relapsing-remitting multiple sclerosis (P2.198)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27794114" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28715536" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28715536" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30777657" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Intracerebral haemorrhage during alemtuzumab administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30777657" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Intracerebral haemorrhage during alemtuzumab administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29178444" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
